RC
PVLA

RBF Capital’s Palvella Therapeutics PVLA Stock Holding History

RBF Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-625
Closed -$114K – 419
2020
Q1 		$114K Sell
625
-75
-11% -$18.9K 0.01% 337
2019
Q4 		$202K Hold
700
– – 0.02% 343
2019
Q3 		$191K Hold
700
– – 0.02% 332
2019
Q2 		$263K Sell
700
-40
-5% -$11.9K 0.03% 307
2019
Q1 		$198K Sell
740
-2,773
-79% -$659K 0.02% 327
2018
Q4 		$747K Buy
+3,513
New +$1.09M 0.1% 170
2018
Q1 		– Sell
-313
Closed -$189K – 396
2017
Q4 		$189K Hold
313
– – 0.02% 327
2017
Q3 		$155K Hold
313
– – 0.02% 329
2017
Q2 		$127K Hold
313
– – 0.02% 321
2017
Q1 		$65K Hold
313
– – 0.01% 351
2016
Q4 		$45K Buy
+313
New +$38.7K 0.01% 363

Other funds holding PVLA

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RBF Capital's PVLA Position: Q2 2020 in Review

RBF Capital sold out of Palvella Therapeutics (PVLA) in Q2 2020, closing a stake of 625 shares — an estimated $114K sold.

RBF Capital first reported a position in PVLA in Q4 2016 and held it in 11 quarters. The position peaked at $747K in Q4 2018. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2020.

  • RBF Capital reported no remaining Palvella Therapeutics position as of Q2 2020 after selling out during the quarter.
  • RBF Capital sold 625 Palvella Therapeutics shares in Q2 2020, an estimated $114K.
  • RBF Capital first reported a position in Palvella Therapeutics in Q4 2016 and held it in 11 quarters.
  • RBF Capital's Palvella Therapeutics position peaked at $747K in Q4 2018.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2020.

Based on RBF Capital's 13F filing for Q2 2020, filed 14 Aug 2020.